REJECTED: Strike 3 for QRxPharma's opioids combo MoxDuo
This article was originally published in Scrip
Executive Summary
The FDA for the third time has rejected QRxPharma's application for its morphine/oxycodone combination drug MoxDuo – news that sent shares of the firm tumbling as low as 15.4% on 27 May.